Intermittent dosing of AZD5363 + Intermittent dosing of AZD5363 + Intermittent dosing of AZD5363
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Castrate-Resistant Prostate Cancer (mCRPC),
Conditions
Metastatic Castrate-Resistant Prostate Cancer (mCRPC),, Efficacy,, Safety and Tolerability,, Pharmacokinetics,, Pharmacodynamics,, Tumour Response.
Trial Timeline
Nov 1, 2012 → Jun 1, 2014
NCT ID
NCT01692262About Intermittent dosing of AZD5363 + Intermittent dosing of AZD5363 + Intermittent dosing of AZD5363
Intermittent dosing of AZD5363 + Intermittent dosing of AZD5363 + Intermittent dosing of AZD5363 is a phase 1 stage product being developed by AstraZeneca for Metastatic Castrate-Resistant Prostate Cancer (mCRPC),. The current trial status is completed. This product is registered under clinical trial identifier NCT01692262. Target conditions include Metastatic Castrate-Resistant Prostate Cancer (mCRPC),, Efficacy,, Safety and Tolerability,.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01692262 | Phase 1 | Completed |
Competing Products
20 competing products in Metastatic Castrate-Resistant Prostate Cancer (mCRPC),